Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer. 

Biotechnology

Iovance Biotherapeutics

Frederick G. Vogt

Joseph Yglesias

Sean Rocca

Kerry Elizabeth Wilson Esq.

Asq Cqa Ulises Villavicencio

Stefanie Bulilan

Renee Doggett

Jim Kirk

Mariam Mirgoli

Nicholas Rojeski

Jessica Reckner

Ahmed Tawashi

Hequn Yin

Kevin Smyth

Jim Ziegler

Howard B. Johnson

Jean-Marc Bellemin

Friedrich Graf Finckenstein

Tracy Winton

Brian Shew

Igor Bilinsky

The Commercial and Market Access team at Iovance Biotherapeutics is responsible for developing and executing strategies to ensure that the company's innovative T cell-based therapies reach cancer patients effectively. This involves coordinating with supply chain, logistics, pricing, and distribution channels, as well as engaging in external affairs to facilitate market access and optimize commercial operations globally.

Commercial and Market Access

Directors Team

Medical and Clinical Affairs

Quality and Compliance

Commercial and Market Access

About

Team members

Other teams at Iovance Biotherapeutics

Directors Team

Medical and Clinical Affairs

Quality and Compliance